Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
聯合診斷2023年第四季度GAAP每股收益（0.50）未達到預期（0.20）美元，銷售額355.5萬美元未達到362.5萬美元的預期
Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.20) by 150 percent. The company reported quarterly sales of $3.555 million which missed the analyst consensus estimate of $3.625 million by 1.93 percent. This is a 153.75 percent increase over sales of $1.401 million the same period last year.
Co-Diagnostics（納斯達克股票代碼：CODX）公佈的季度虧損爲每股0.50美元，比分析師普遍預期的0.20美元（0.20美元）低150％。該公司公佈的季度銷售額爲355.5萬美元，比分析師普遍預期的362.5萬美元低1.93％。這比去年同期的14.01億美元銷售額增長了153.75％。